Last reviewed · How we verify
Nickel Desensitization Using Topical Therapy
Nickel contact dermatitis (eczema) is one of the most common allergic conditions affecting the skin. This is a study looking at potentially desensitizing nickel-allergic patients to their allergy using anti-inflammatory ointments applied to the skin (arm). Application of these ointments (ie. modified Vitamin D) has been shown to increase specific immune cells (T regulatory cells), which play a role in preventing immune activation and subsequently inflammation. The investigators propose use of topical anti-inflammatory agents (corticosteroids, modified Vitamin D, or both) may desensitize patients with nickel allergy.
Details
| Lead sponsor | University of British Columbia |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 24 |
| Start date | 2011-08 |
| Completion | 2012-06 |
Conditions
- Allergic Contact Dermatitis
Interventions
- Calcipotriol, Betamethasone, Calcipotriol & Betamethasone
Primary outcomes
- Change in contact dermatitis response to nickel allergen at 5 weeks after topical desensitization — All study subjects will be evaluated after each patch test session (weeks 1, 3, 5). The final outcome to assess for desensitization will be evaluated at week 5.
Erythema, induration, blistering of the skin will be noted. The standardized Likert scale (0-3+) will be used as follows: 1. \+ Weak (non-vesicular) reaction: erythema, infiltration, possibly papules 2. ++ Strong (edematous or vesicular) reaction 3. +++ Extreme (spreading, bullous or ulcerative) reaction * Negative reaction
Countries
Canada